COVID-19

The CDC has updated its COVID-19 vaccine guidance for children and pregnant individuals, sparking a debate among health experts and concerns over insurance coverage.

Amid intensified scrutiny of COVID-19 vaccines at HHS, Moderna’s mRNA-1283 COVID-19 vaccine was granted FDA approval for patients 65 years and older and patients aged 12 to 64 years with at least 1 or more underlying risk factors for severe COVID-19.

The change is poised to impact countless individuals who may have sought a COVID-19 vaccine this upcoming respiratory season.

Following a meeting of the Vaccines and Related Biological Products Advisory Committee, the FDA announced its recommendation of COVID-19 vaccines targeting LP.8.1, a strain of the JN.1 variant that has become dominant in the US.

In a major policy shift, officials from the FDA announced a new regulatory framework for COVID-19 vaccinations, prioritizing adults 65 years and older and individuals with serious comorbidities putting them at high risk for severe COVID-19.

COVID-19 can reshape one’s academic journey and outlook on life.

The vaccine, indicated with a restriction on use for those younger than 65 years and without comorbidities, was proven safe and effective in a series of large clinical trials, and marks the first protein-based vaccine to be approved in the United States.

A new multicomponent vaccine, mRNA-1083, shows promise in enhancing immune responses against influenza and COVID-19, addressing vaccine hesitancy effectively.

A rehabilitation method commonly used in patients who experience a traumatic brain injury was found to improve symptoms of long COVID, including brain fog and measures of daily living.

Research reveals that children face significant long-term health risks, including kidney, gastrointestinal, and cardiovascular issues, after COVID-19 infection.

New research highlights the long-lasting effectiveness of mRNA COVID-19 vaccines, showing sustained B-cell and antibody responses in health care workers over 3 years.

With a more direct mechanism of action against viral replication compared with standard treatments, the small interfering RNA (siRNA)-based MIR 19 treatment could revolutionize outpatient COVID-19 treatment.

Monetary incentives to receive a COVID-19 vaccine at a public vaccination event may have inadvertently turned away others from receiving a booster, emphasizing the importance of recognizing spillover in trials addressing vaccine hesitancy.

The poll also showed that social media and general media coverage influenced about 33% of participants to not get vaccinated.

Pharmacists play a key role in COVID-19 management by educating patients on treatment, monitoring drug interactions, promoting vaccination, and addressing hesitancy.

As the COVID-19 pandemic moves into an endemic phase, the major impacts on drug research, collaboration, and use of new technologies due to the spread of the virus warrant recognition.

A district leader at CVS Health emphasizes that patients should get tested, be up to date with immunizations, and staying home and reach out to health care professionals when experiencing symptoms.

The 3CL protease inhibitor is designed to suppress the replication of SARS-CoV-2, preventing COVID-19 illness, even if a household member is infected.

The pandemic showcased the resiliency and adaptability of pharmacists.

COVID-19 changed the personal and professional lives of all pharmacy workforce members. But what now?

In older postmenopausal women, leukocyte count was found to be an independent predictor of long COVID symptom severity, highlighting its potential for use as a novel symptom biomarker.

New results shed light on the ineffectiveness of the combination antiviral therapy in patients vaccinated against COVID-19.

The test results are available in as little as 20 minutes.

New data from the longest known trial of pediatrics and adolescents in the postacute phase of COVID-19 show they are at a heightened risk of gastrointestinal tract symptoms.

Emerging data indicate that COVID-19 is also characterized by inflammation present in the heart and other organs

Investigators noted that the differences between the 3 respiratory infections were not as pronounced during the 2023-2024 season.

Through similar targeting of the RdRp enzyme, these treatments could offer groundbreaking new options for patients with COVID-19 if proven effective in real-world trials.

Patients recovering from COVID-19 and caregivers reported how some social determinants of health were helpful in their recovery, while others led to difficult social and mental challenges.

Engaging with the community, providing transparent information to patients, and using noncoercive methods of encouragement are strategies to reduce COVID-19 vaccine hesitancy.

The finding could help better treat patients with long COVID, as pharmacists and treatment providers can look out for ME/CFS symptoms.